AAPL311.74-4.49 (-1.42%) ▼|ABBV249.21+0.43 (+0.17%) ▲|ABT105.72+0.20 (+0.19%) ▲|ACN176.75-2.28 (-1.27%) ▼|ADBE257.46+0.20 (+0.08%) ▲|AMAT467.39-5.41 (-1.14%) ▼|AMD522.42+16.68 (+3.30%) ▲|AMGN390.72-2.46 (-0.62%) ▼|AMT175.63-0.10 (-0.06%) ▼|AMZN252.23-4.74 (-1.84%) ▼|AVGO364.57-3.99 (-1.08%) ▼|AXP322.83-3.28 (-1.00%) ▼|BA208.75-1.98 (-0.94%) ▼|BAC62.78+0.39 (+0.62%) ▲|BKNG172.74-7.57 (-4.20%) ▼|BLK1,079.84-15.54 (-1.42%) ▼|BMY64.62-0.07 (-0.11%) ▼|BNY163.39+0.54 (+0.33%) ▲|BRK-B509.18+3.35 (+0.66%) ▲|C138.16+1.42 (+1.03%) ▲|CAT817.45-5.04 (-0.61%) ▼|CL88.31-0.11 (-0.12%) ▼|CMCSA24.54-1.80 (-6.82%) ▼|COF212.55-1.41 (-0.66%) ▼|COP136.74+1.70 (+1.26%) ▲|COST899.91-10.27 (-1.13%) ▼|CRM247.38-1.74 (-0.70%) ▼|CSCO109.72+0.55 (+0.50%) ▲|CVS95.60-0.47 (-0.49%) ▼|CVX213.33+3.53 (+1.68%) ▲|DE674.23-6.51 (-0.96%) ▼|DHR205.10-0.13 (-0.06%) ▼|DIS104.63-0.43 (-0.41%) ▼|DUK120.02-1.22 (-1.01%) ▼|EMR151.40-0.76 (-0.50%) ▼|FDX309.89-4.24 (-1.35%) ▼|GD353.01-3.57 (-1.00%) ▼|GE325.34-9.57 (-2.86%) ▼|GEV953.97-17.35 (-1.79%) ▼|GILD145.95-0.69 (-0.47%) ▼|GM84.97-0.82 (-0.96%) ▼|GOOG329.06-6.32 (-1.88%) ▼|GOOGL331.34-7.02 (-2.07%) ▼|GS1,036.29-0.24 (-0.02%) ▼|HD310.83-2.87 (-0.91%) ▼|HON206.58-1.66 (-0.80%) ▼|IBM236.16+4.07 (+1.75%) ▲|INTC105.65+1.18 (+1.12%) ▲|INTU315.59-3.34 (-1.05%) ▼|ISRG351.85+1.69 (+0.48%) ▲|JNJ267.83-1.29 (-0.48%) ▼|JPM355.26+1.75 (+0.50%) ▲|KO87.87-0.50 (-0.56%) ▼|LIN466.03-2.35 (-0.50%) ▼|LLY1,126.41+2.50 (+0.22%) ▲|LMT525.97-10.18 (-1.90%) ▼|LOW198.81-2.00 (-0.99%) ▼|LRCX315.64-4.78 (-1.49%) ▼|MA569.75-1.15 (-0.20%) ▼|MCD255.40-0.41 (-0.16%) ▼|MDLZ61.95+0.32 (+0.52%) ▲|MDT92.48+0.09 (+0.10%) ▲|META653.30+39.82 (+6.49%) ▲|MMM164.81-2.72 (-1.62%) ▼|MO67.77-0.40 (-0.59%) ▼|MRK148.19-0.27 (-0.18%) ▼|MS216.40+0.16 (+0.07%) ▲|MSFT492.84-1.11 (-0.22%) ▼|MU1,022.62+22.36 (+2.24%) ▲|NEE82.89-0.95 (-1.13%) ▼|NFLX76.38-0.40 (-0.51%) ▼|NKE37.21-0.90 (-2.35%) ▼|NOW131.20-3.01 (-2.24%) ▼|NVDA224.25-1.48 (-0.66%) ▼|ORCL163.14+0.62 (+0.38%) ▲|PEP136.57-1.88 (-1.36%) ▼|PFE27.93+0.14 (+0.49%) ▲|PG142.94-2.64 (-1.81%) ▼|PLTR170.85+0.55 (+0.32%) ▲|PM185.24+0.51 (+0.27%) ▲|QCOM175.09+1.00 (+0.57%) ▲|RTX198.76-0.05 (-0.03%) ▼|SBUX100.83-1.19 (-1.16%) ▼|SCHW107.34+0.47 (+0.44%) ▲|SO88.21-0.78 (-0.88%) ▼|SPG206.38-3.25 (-1.55%) ▼|T25.10-0.51 (-1.97%) ▼|TMO606.16+3.14 (+0.52%) ▲|TMUS177.68-4.01 (-2.21%) ▼|TSLA368.98+0.82 (+0.22%) ▲|TXN261.45+2.53 (+0.98%) ▲|UBER71.71-1.42 (-1.94%) ▼|UNH392.19-8.65 (-2.16%) ▼|UNP284.77-3.68 (-1.28%) ▼|UPS99.34-1.15 (-1.14%) ▼|USB62.18-0.31 (-0.50%) ▼|V368.41-0.23 (-0.06%) ▼|VZ49.60-0.82 (-1.62%) ▼|WFC89.63+1.67 (+1.90%) ▲|WMT105.88-0.17 (-0.16%) ▼|XOM164.66+4.00 (+2.49%) ▲|AAPL311.74-4.49 (-1.42%) ▼|ABBV249.21+0.43 (+0.17%) ▲|ABT105.72+0.20 (+0.19%) ▲|ACN176.75-2.28 (-1.27%) ▼|ADBE257.46+0.20 (+0.08%) ▲|AMAT467.39-5.41 (-1.14%) ▼|AMD522.42+16.68 (+3.30%) ▲|AMGN390.72-2.46 (-0.62%) ▼|AMT175.63-0.10 (-0.06%) ▼|AMZN252.23-4.74 (-1.84%) ▼|AVGO364.57-3.99 (-1.08%) ▼|AXP322.83-3.28 (-1.00%) ▼|BA208.75-1.98 (-0.94%) ▼|BAC62.78+0.39 (+0.62%) ▲|BKNG172.74-7.57 (-4.20%) ▼|BLK1,079.84-15.54 (-1.42%) ▼|BMY64.62-0.07 (-0.11%) ▼|BNY163.39+0.54 (+0.33%) ▲|BRK-B509.18+3.35 (+0.66%) ▲|C138.16+1.42 (+1.03%) ▲|CAT817.45-5.04 (-0.61%) ▼|CL88.31-0.11 (-0.12%) ▼|CMCSA24.54-1.80 (-6.82%) ▼|COF212.55-1.41 (-0.66%) ▼|COP136.74+1.70 (+1.26%) ▲|COST899.91-10.27 (-1.13%) ▼|CRM247.38-1.74 (-0.70%) ▼|CSCO109.72+0.55 (+0.50%) ▲|CVS95.60-0.47 (-0.49%) ▼|CVX213.33+3.53 (+1.68%) ▲|DE674.23-6.51 (-0.96%) ▼|DHR205.10-0.13 (-0.06%) ▼|DIS104.63-0.43 (-0.41%) ▼|DUK120.02-1.22 (-1.01%) ▼|EMR151.40-0.76 (-0.50%) ▼|FDX309.89-4.24 (-1.35%) ▼|GD353.01-3.57 (-1.00%) ▼|GE325.34-9.57 (-2.86%) ▼|GEV953.97-17.35 (-1.79%) ▼|GILD145.95-0.69 (-0.47%) ▼|GM84.97-0.82 (-0.96%) ▼|GOOG329.06-6.32 (-1.88%) ▼|GOOGL331.34-7.02 (-2.07%) ▼|GS1,036.29-0.24 (-0.02%) ▼|HD310.83-2.87 (-0.91%) ▼|HON206.58-1.66 (-0.80%) ▼|IBM236.16+4.07 (+1.75%) ▲|INTC105.65+1.18 (+1.12%) ▲|INTU315.59-3.34 (-1.05%) ▼|ISRG351.85+1.69 (+0.48%) ▲|JNJ267.83-1.29 (-0.48%) ▼|JPM355.26+1.75 (+0.50%) ▲|KO87.87-0.50 (-0.56%) ▼|LIN466.03-2.35 (-0.50%) ▼|LLY1,126.41+2.50 (+0.22%) ▲|LMT525.97-10.18 (-1.90%) ▼|LOW198.81-2.00 (-0.99%) ▼|LRCX315.64-4.78 (-1.49%) ▼|MA569.75-1.15 (-0.20%) ▼|MCD255.40-0.41 (-0.16%) ▼|MDLZ61.95+0.32 (+0.52%) ▲|MDT92.48+0.09 (+0.10%) ▲|META653.30+39.82 (+6.49%) ▲|MMM164.81-2.72 (-1.62%) ▼|MO67.77-0.40 (-0.59%) ▼|MRK148.19-0.27 (-0.18%) ▼|MS216.40+0.16 (+0.07%) ▲|MSFT492.84-1.11 (-0.22%) ▼|MU1,022.62+22.36 (+2.24%) ▲|NEE82.89-0.95 (-1.13%) ▼|NFLX76.38-0.40 (-0.51%) ▼|NKE37.21-0.90 (-2.35%) ▼|NOW131.20-3.01 (-2.24%) ▼|NVDA224.25-1.48 (-0.66%) ▼|ORCL163.14+0.62 (+0.38%) ▲|PEP136.57-1.88 (-1.36%) ▼|PFE27.93+0.14 (+0.49%) ▲|PG142.94-2.64 (-1.81%) ▼|PLTR170.85+0.55 (+0.32%) ▲|PM185.24+0.51 (+0.27%) ▲|QCOM175.09+1.00 (+0.57%) ▲|RTX198.76-0.05 (-0.03%) ▼|SBUX100.83-1.19 (-1.16%) ▼|SCHW107.34+0.47 (+0.44%) ▲|SO88.21-0.78 (-0.88%) ▼|SPG206.38-3.25 (-1.55%) ▼|T25.10-0.51 (-1.97%) ▼|TMO606.16+3.14 (+0.52%) ▲|TMUS177.68-4.01 (-2.21%) ▼|TSLA368.98+0.82 (+0.22%) ▲|TXN261.45+2.53 (+0.98%) ▲|UBER71.71-1.42 (-1.94%) ▼|UNH392.19-8.65 (-2.16%) ▼|UNP284.77-3.68 (-1.28%) ▼|UPS99.34-1.15 (-1.14%) ▼|USB62.18-0.31 (-0.50%) ▼|V368.41-0.23 (-0.06%) ▼|VZ49.60-0.82 (-1.62%) ▼|WFC89.63+1.67 (+1.90%) ▲|WMT105.88-0.17 (-0.16%) ▼|XOM164.66+4.00 (+2.49%) ▲|
27.1 C
New York
Wednesday, September 9, 2026

Tag: medicines

newssourceFORcompanyinformationcontent1releasesmarket

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)NEW YORK and NORTH CHICAGO, Ill., July 10, 2025...

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer rates are...

Varda Announces $187 million in Series C Funding to Make Medicines in Space

The El Segundo-based start-up is building infrastructure to support manufacturing in microgravity and test hypersonic reentry technologies. EL SEGUNDO, Calif., July 10, 2025 /PRNewswire/ -- Varda...

DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK Research Project

DXS INTERNATIONAL PLC (AQSE: DXSP)

Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025

RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Data from Orbit and Cosmic studies expected around the end of the year 
Data from Orbit and Cosmic studies expected around the end of the year

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results

Conference Call and Webcast Scheduled for Wednesday, July 30 SAN DIEGO, July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it...

Inside information: Orion upgrades full-year outlook for 2025

ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
9 JULY 2025 at 13.00 EEST
        

Zentiva and Lupin Sign License and Supply Agreement for TNF alpha inhibitor biosimilar medicine

PRAGUE, July 9, 2025 /PRNewswire/ -- Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for commercialization of...

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Alvotech acquires capability and added flexibility in assembly and packaging with acquisition of Ivers-Lee Group

Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)

London – 9 July 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary IgA nephropathy (IgAN).

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicines

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers